IPX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IperionX (IPX) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants an immediate decision. The business has some strong event-driven positives, but the stock’s technical setup is still weak and the recent upside appears better suited for monitoring than for committing capital today. If you already own it, hold; if you do not, I would not buy at this exact level.
IPX is trading near 28.76, essentially flat versus the prior close, but the broader tape is not constructive. MACD histogram is negative at -0.275, RSI_6 is neutral at 42.991, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5. That means the stock is still in a weak trend despite being close to pivot support at 28.69. Key levels to watch are support at 26.03 and resistance at 31.35. The short-term pattern data suggests a modest next-day bounce probability, but the next-month expectation is negative, which weakens the long-term entry case.
Recent news is clearly supportive. IperionX completed the acquisition of Camden critical mineral assets in Tennessee, which expands project scale and development potential. It also secured $6.6 million in defense funding to expand titanium manufacturing capabilities and improve efficiency in Virginia. Analyst sentiment is constructive, with multiple Buy ratings and repeated $55 price targets, suggesting Wall Street sees meaningful upside if execution continues.
The chart is still weak, with bearish moving averages and negative MACD momentum. Hedge funds and insiders are neutral, so there is no strong ownership signal backing the move. There is no recent congress trading data, and no politician or influential figure activity was provided. The stock’s one-month pattern outlook is negative, which conflicts with the positive news flow and suggests the market has not yet fully confirmed the catalyst story.
No usable latest-quarter financial snapshot was provided due to a data error, so I cannot verify revenue or profit growth from the most recent quarter season. Based on the provided information, the company’s core story is still development-stage execution rather than proven earnings strength, with recent catalysts centered on asset expansion, defense funding, and manufacturing scale-up rather than reported quarterly financial acceleration.
Analyst sentiment has improved over the last two months. Texas Capital initiated coverage on 2026-06-29/30 with a Buy and $55 target, and BTIG raised its target to $55 from $40 on 2026-06-05 while keeping Buy. Earlier, Alliance Global had already lowered its target to $53 from $60 on 2026-04-28 but maintained Buy. Overall, Wall Street remains bullish with a roughly $53-$55 target range, and the pros appear to view IPX as an attractive long-duration critical materials and titanium platform. The con view is that valuation is not grounded here due to missing financials, and the market is still not confirming the thesis technically.
